7-OH Users Are Stockpiling Ahead of a DEA Ban
The opioid-like compound, which is found in kratom, can cause brutal withdrawal symptoms and will soon be a controlled substance. Some users tell WIRED it has relieved their pain and anxiety.
The impending DEA ban on 7-OH, an opioid-like compound found in kratom, has significant implications for the tech industry, particularly in the realm of digital health and wellness. As users stockpile the substance ahead of the ban, it highlights the complex intersection of technology, healthcare, and regulation. The fact that some users rely on 7-OH to manage their pain and anxiety underscores the need for innovative, tech-enabled solutions to address the ongoing opioid crisis and mental health concerns.
The DEA's decision to classify 7-OH as a controlled substance will likely have far-reaching consequences for online communities and forums where users discuss and share information about the substance. Technology companies, especially those involved in healthcare and social media, will need to navigate the regulatory landscape and ensure compliance with the new rules. This may involve monitoring and moderating online discussions, as well as implementing measures to prevent the illicit sale and distribution of 7-OH.
As the ban takes effect, it will be essential to watch how the tech industry responds to the changing regulatory environment and the evolving needs of users who rely on 7-OH for pain and anxiety relief. Companies developing digital health solutions, such as telemedicine platforms and mental health apps, may see an opportunity to fill the gap left by the ban. Additionally, researchers and developers may focus on creating alternative, tech-enabled treatments for pain and anxiety, potentially leading to breakthroughs in the field of digital therapeutics.
Originally reported by wired.com. NewsChannels adds analysis for technology readers.